Mr. Moffet or Mr. Clarkson are probably better positioned to answer that. I can tell you something anecdotally, and it's more related to our future work plans and the scoping of this work.
Often when we scope work we do a number of interviews with stakeholders to find out what the issues are, what their concerns are. I think there was a generally held view that the new substance notification procedures under CEPA were okay. Nobody raised major problems with those provisions, and that's why we've tended to not look at them; we've tended to look where there are problems.
But inside the science and the robustness of industry-generated data...one of the departments needs to talk about that.